Login / Signup

Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease.

Andree H KoopPaul M TraversSahil KhannaDarrell S PardiFrancis A FarrayeJana G Hashash
Published in: Journal of gastroenterology and hepatology (2023)
In this cohort of patients with inflammatory bowel disease and C. difficile infection, 60.6% responded to treatment with fidaxomicin. Of those who did not respond, fecal microbiota transplantation was an effective therapy.
Keyphrases
  • clostridium difficile
  • patients with inflammatory bowel disease
  • combination therapy
  • cell therapy
  • mesenchymal stem cells